ABO Blood Group Matching for Cryoprecipitate Transfusion
Yes, donor and recipient blood groups should be the same for cryoprecipitate transfusion according to current guidelines. 1
Primary Recommendation
The 2025 Association of Anaesthetists guidelines explicitly state: "Donor and recipient blood groups should be the same for FFP and cryoprecipitate transfusion." 1 This represents the most recent and authoritative guidance on this practice.
When ABO-Identical is Not Available
If the patient's blood group is unknown or ABO-identical cryoprecipitate is unavailable:
- ABO non-identical plasma components are acceptable only if they have 'low titre' anti-A or anti-B activity 1
- Group O components should only be given to group O recipients 1
This is a critical safety caveat that prevents high-titre antibody exposure.
Rh Matching Considerations
The guidelines do not specifically mandate Rh (D antigen) matching for cryoprecipitate in the same way they do for red blood cells. The primary concern is ABO compatibility due to the plasma content and potential for anti-A/anti-B antibodies.
Clinical Rationale
Cryoprecipitate is a plasma-derived product containing residual plasma (typically 20-40 mL per unit, or 100-200 mL per pooled bag of 5 units). This plasma contains ABO antibodies that can cause:
- Hemolysis from donor antibodies attacking recipient red cells
- Immune complex formation
- Potential endothelial and platelet injury 2
While the volume is smaller than FFP, the risk is not negligible, particularly when multiple units are administered during massive transfusion protocols.
Evidence Nuances
Conflicting perspectives exist:
- A 2021 Canadian study 3 calculated the probability of transfusing high-titre cryoprecipitate (>1:100) as less than 1 in 3 million, supporting transfusion without ABO matching in adults
- However, a 2022 post-hoc analysis of the FIBRES trial 4 found increased post-operative anemia (28.3% vs 14.2%, p=0.01) in patients receiving ABO-incompatible cryoprecipitate
- A 2011 study 5 demonstrated that ABO-identical transfusion policies were associated with reduced red cell transfusion requirements and improved outcomes
- Case reports 6 document immunohematological complications from out-of-group cryoprecipitate transfusion
Despite mixed research evidence, the guideline recommendation is clear and should be followed.
Practical Implementation
In clinical practice:
- Request ABO-identical cryoprecipitate as standard practice
- Document when ABO-identical product is unavailable
- If using non-identical product, ensure it is low-titre tested
- Be particularly cautious with large-volume transfusions (massive transfusion protocols, obstetric hemorrhage)
- Monitor for signs of hemolysis when ABO-incompatible products are used
Common Pitfalls to Avoid
- Assuming cryoprecipitate doesn't require matching because of small plasma volume—the guidelines explicitly require matching 1
- Giving group O cryoprecipitate universally—this should only go to group O recipients 1
- Ignoring antibody titres—if non-identical product must be used, verify low-titre status
- Not documenting deviations—when ABO-identical is unavailable, document the clinical justification
The 2025 guidelines represent the current standard of care and should supersede older practices that may have been more permissive about ABO compatibility for cryoprecipitate transfusion.